AI Article Synopsis
- The study investigates healthcare professionals' knowledge, attitudes, and practices regarding adverse drug reactions (ADRs) reporting in primary healthcare settings in South Africa.
- Despite a generally positive attitude towards reporting ADRs, actual reporting rates are very low, with 16% of respondents reporting ADRs and many lacking knowledge on how and when to report.
- The findings indicate a critical need for improved education and training for healthcare providers in order to enhance ADR reporting practices.
Article Abstract
Purpose: Adverse drug reactions (ADRs) have an appreciable impact on patients' health. Little is known however about ADR reporting in ambulatory care environments especially in low- and middle-income countries. Consequently, our aim was to determine knowledge, attitudes and practices (KAP) among health care professionals (HCPs) towards ADR reporting in primary health care (PHC) facilities in South Africa. The findings will be used to direct future activities.
Methods: Descriptive, cross-sectional design using quantitative methodology among 8 public sector community health care centres and 40 PHC clinics in the Tshwane Health District, Gauteng Province. A self-administered questionnaire was distributed to 218 HCPs, including all key groups.
Results: A total of 200 responses were received (91.7%). Although an appropriate attitude towards ADR reporting existed, the actual frequency of ADR reporting was low (16.0%). Of the respondents, 60.5% did not know how to report, where to report or when to report an ADR and 51.5% said the level of their clinical knowledge made it difficult to decide whether or not an ADR had occurred. Over 97.5% stated they should be reporting ADRs with 89% feeling that ADR reporting is a professional obligation and over 70% that ADR reporting should be compulsory. When results were combined, the overall mean score in terms of positive or preferred practices for ADR reporting was 24.6% with pharmacists having the highest scores.
Conclusion: Under-reporting of ADRs with gaps in KAP was evident. There is a serious and urgent need for education and training of HCPs on ADR reporting in South Africa.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306046 | PMC |
| http://dx.doi.org/10.1007/s00228-020-02862-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Romosozumab adverse event profile: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023.
Aging Clin Exp Res
January 2025
Department of Spine Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an, 710054, Shaanxi, China.
Objective: This study aims to analyze adverse drug events (ADE) related to romosozumab from the second quarter of 2019 to the third quarter of 2023 from FAERS database.
Methods: The ADE data related to romosozumab from 2019 Q2 to 2023 Q3 were collected. After data normalization, four signal strength quantification algorithms were used: ROR (Reporting Odds Ratios), PRR (Proportional Reporting Ratios), BCPNN (Bayesian Confidence Propagation Neural Network), and EBGM (Empirical Bayesian Geometric Mean).
Lactic acidosis with metformin accumulation in the intensive care units of the Nord Pas de Calais region: A known serious adverse event that can be better prevented.
Therapie
December 2024
CHU Lille, University Lille, Intensive Médecine Reanimation, 59000 Lille, France.
Article Synopsis
- The study focused on identifying situations that lead to metformin-associated lactic acidosis (MALA) in ICU patients and evaluating its preventability.
- A total of 198 MALA cases were assessed, with 19.2% resulting in death; the majority of patients had acute events like dehydration or severe infections that contributed to the condition.
- The findings indicated that MALA is often preventable, highlighting the need for better physician and patient education regarding metformin use during high-risk medical situations.
Study on the Chemical Composition and Multidrug Resistance Reversal Activity of (Euphorbiaceae).
Int J Mol Sci
January 2025
Key Laboratory of Xinjiang Phytomedicine Resource and Uilization, Ministry of Education, Shihezi 832002, China.
belongs to the family Euphorbiaceae and is widely distributed in northern Xinjiang, making it a characteristic plant of the region in Xinjiang, China. The chemical composition and biological activity of have not yet been reported, although certain compounds isolated from plants in Xinjiang, China, have demonstrated exceptional multidrug resistance (MDR) reversal. This study aims to investigate the chemical components present in with the potential to reverse MDR.
View Article and Find Full Text PDFPlantaginis Herba attenuates adriamycin-induced nephropathy: Molecular mechanism insights by integrated transcriptomic and experimental validation.
J Ethnopharmacol
January 2025
Henan University of Chinese Medicine, 156 Jinshui East Road, Zhengzhou, 450046, China; The Engineering and Technology Center for Chinese Medicine Development of Henan Province, 156 Jinshui East Road, Zhengzhou, 450046, China. Electronic address:
Ethnopharmacological Relevance: The Chinese herbal Plantaginis Herba (PL) is one of the most widely used plants for both medicinal and dietary purposes. Plantaginis Herba is the main medicine used in a traditional Chinese prescription called Cheqiancao decoction, and it is known for its liver and kidney protective properties.
Aim Of The Study: The aim of the present study was to explore the interventions and mechanisms of PL in ADR nephropathy by performing an integrated analysis of in vitro and in vivo experiments.
Medication Hazards and Outcome Patterns of Pediatric Drug-Associated Liver Injury in Taiwan: An Analysis of 1998-2017 Spontaneous Adverse Drug Reaction Reports.
Drugs Real World Outcomes
January 2025
School of Pharmacy, College of Medicine, National Taiwan University, Taipei, 100025, Taiwan.
Background And Objectives: Accumulating pediatric efficacy and safety data on drug use is inherently challenging yet essential. This study aimed to analyze the frequency and compute the odds of pediatric drug-associated liver injury across age groups (early childhood, middle childhood, and adolescence) and therapeutic categories using adverse drug reactions (ADRs) reporting data spanning nearly two decades.
Methods: We analyzed the reports of suspected ADRs occurring in children and adolescents in the Taiwan National Adverse Drug Reaction Reporting System during the period from May 1998 until July 2017.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!